Cargando…

Comparing the cost-per-QALYs gained and cost-per-DALYs averted literatures

Background: We examined the similarities and differences between studies using two common metrics used in cost-effectiveness analyses (CEAs): cost per quality-adjusted life year (QALY) gained and cost per disability-adjusted life year (DALY) averted. Methods: We used the Tufts Medical Center CEA Reg...

Descripción completa

Detalles Bibliográficos
Autores principales: Neumann, Peter J., Anderson, Jordan E., Panzer, Ari D., Pope, Elle F., D'Cruz, Brittany N., Kim, David D., Cohen, Joshua T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: F1000 Research Limited 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5801595/
https://www.ncbi.nlm.nih.gov/pubmed/29431169
http://dx.doi.org/10.12688/gatesopenres.12786.2
_version_ 1783298375834140672
author Neumann, Peter J.
Anderson, Jordan E.
Panzer, Ari D.
Pope, Elle F.
D'Cruz, Brittany N.
Kim, David D.
Cohen, Joshua T.
author_facet Neumann, Peter J.
Anderson, Jordan E.
Panzer, Ari D.
Pope, Elle F.
D'Cruz, Brittany N.
Kim, David D.
Cohen, Joshua T.
author_sort Neumann, Peter J.
collection PubMed
description Background: We examined the similarities and differences between studies using two common metrics used in cost-effectiveness analyses (CEAs): cost per quality-adjusted life year (QALY) gained and cost per disability-adjusted life year (DALY) averted. Methods: We used the Tufts Medical Center CEA Registry, which contains English-language cost-per-QALY gained studies, and the Global Cost-Effectiveness Analysis (GHCEA) Registry, which contains cost-per-DALY averted studies. We examined study characteristics, including intervention type, sponsor, country, and primary disease, and also compared the number of published CEAs to disease burden for major diseases and conditions across geographic regions. Results: We identified 6,438 cost-per-QALY and 543 cost-per-DALY studies published through 2016 and observed rapid growth for both literatures. Cost-per-QALY studies most often examined pharmaceuticals and interventions in high-income countries. Cost-per-DALY studies predominantly focused on infectious disease interventions and interventions in low and lower-middle income countries. We found that while diseases imposing a larger burden tend to receive more attention in the cost-effectiveness analysis literature, the number of publications for some diseases and conditions deviates from this pattern, suggesting “under-studied” conditions (e.g., neonatal disorders) and “over-studied” conditions (e.g., HIV and TB). Conclusions: The CEA literature has grown rapidly, with applications to diverse interventions and diseases.  The publication of fewer studies than expected for some diseases given their imposed burden suggests funding opportunities for future cost-effectiveness research.
format Online
Article
Text
id pubmed-5801595
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher F1000 Research Limited
record_format MEDLINE/PubMed
spelling pubmed-58015952018-02-07 Comparing the cost-per-QALYs gained and cost-per-DALYs averted literatures Neumann, Peter J. Anderson, Jordan E. Panzer, Ari D. Pope, Elle F. D'Cruz, Brittany N. Kim, David D. Cohen, Joshua T. Gates Open Res Research Article Background: We examined the similarities and differences between studies using two common metrics used in cost-effectiveness analyses (CEAs): cost per quality-adjusted life year (QALY) gained and cost per disability-adjusted life year (DALY) averted. Methods: We used the Tufts Medical Center CEA Registry, which contains English-language cost-per-QALY gained studies, and the Global Cost-Effectiveness Analysis (GHCEA) Registry, which contains cost-per-DALY averted studies. We examined study characteristics, including intervention type, sponsor, country, and primary disease, and also compared the number of published CEAs to disease burden for major diseases and conditions across geographic regions. Results: We identified 6,438 cost-per-QALY and 543 cost-per-DALY studies published through 2016 and observed rapid growth for both literatures. Cost-per-QALY studies most often examined pharmaceuticals and interventions in high-income countries. Cost-per-DALY studies predominantly focused on infectious disease interventions and interventions in low and lower-middle income countries. We found that while diseases imposing a larger burden tend to receive more attention in the cost-effectiveness analysis literature, the number of publications for some diseases and conditions deviates from this pattern, suggesting “under-studied” conditions (e.g., neonatal disorders) and “over-studied” conditions (e.g., HIV and TB). Conclusions: The CEA literature has grown rapidly, with applications to diverse interventions and diseases.  The publication of fewer studies than expected for some diseases given their imposed burden suggests funding opportunities for future cost-effectiveness research. F1000 Research Limited 2018-03-05 /pmc/articles/PMC5801595/ /pubmed/29431169 http://dx.doi.org/10.12688/gatesopenres.12786.2 Text en Copyright: © 2018 Neumann PJ et al. http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Neumann, Peter J.
Anderson, Jordan E.
Panzer, Ari D.
Pope, Elle F.
D'Cruz, Brittany N.
Kim, David D.
Cohen, Joshua T.
Comparing the cost-per-QALYs gained and cost-per-DALYs averted literatures
title Comparing the cost-per-QALYs gained and cost-per-DALYs averted literatures
title_full Comparing the cost-per-QALYs gained and cost-per-DALYs averted literatures
title_fullStr Comparing the cost-per-QALYs gained and cost-per-DALYs averted literatures
title_full_unstemmed Comparing the cost-per-QALYs gained and cost-per-DALYs averted literatures
title_short Comparing the cost-per-QALYs gained and cost-per-DALYs averted literatures
title_sort comparing the cost-per-qalys gained and cost-per-dalys averted literatures
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5801595/
https://www.ncbi.nlm.nih.gov/pubmed/29431169
http://dx.doi.org/10.12688/gatesopenres.12786.2
work_keys_str_mv AT neumannpeterj comparingthecostperqalysgainedandcostperdalysavertedliteratures
AT andersonjordane comparingthecostperqalysgainedandcostperdalysavertedliteratures
AT panzerarid comparingthecostperqalysgainedandcostperdalysavertedliteratures
AT popeellef comparingthecostperqalysgainedandcostperdalysavertedliteratures
AT dcruzbrittanyn comparingthecostperqalysgainedandcostperdalysavertedliteratures
AT kimdavidd comparingthecostperqalysgainedandcostperdalysavertedliteratures
AT cohenjoshuat comparingthecostperqalysgainedandcostperdalysavertedliteratures